Article
Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.
Clinical drug investigation - 1 Nov 2020
Narasimhalu Kaavya, Ang Yoong Kwei, Tan Doreen Su Yin, De Silva Deidre Anne, Tan Kelvin Bryan
Abstract excerpt
BACKGROUND: Patients with ischemic stroke are often treated with clopidogrel monotherapy as part of secondary stroke prevention. The prevalence of loss of function (LOF) mutations in the CYP2C19 gene is higher in Asians than in Western populations. Patients with loss of function (LOF) mutations are at risk for poorer secondary outcomes when prescribed clopidogrel. OBJECTIVE: We aimed to determine the cost...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.